10th Annual Penn State Addiction Conference

J7043

+ Add to Google Calendar + Add to Outlook

The annual Penn State College of Medicine Addiction Conference will be a two-day, hybrid event held in Hershey, Pa., focusing on translational research and clinical practice aspects of substance use research, treatment, education and community engagement. The first day will be focused on clinically relevant translational research and the second on evidence-based clinical applications for treatment of substance use and use disorders. Each day will feature Keynote Speaker presentations.

This event is free and we welcome anyone who wishes to attend from any institution and/or the community at large.

Nov. 11, 2024: Basic and Translational Science Research

Learning Objectives:

1. Use preclinical and clinical data to address the underlying neural substrates mediating substance use disorder, risk factors for the development of the disease and recurrence of use, and novel interventions.
2. Discuss recent and emerging developments, trends, and challenges in basic, translational, clinical, and psychosocial research on the neurobiological mechanisms of substance use and use disorders.
3. Examine research investigating the risk for the development of substance use disorders and factors contributing to recurrence of use.
4. Discuss novel and emerging therapeutics to treat substance use disorder, their pharmacokinetic and physiologic mechanisms of action, and their potential risks to vulnerable populations.

Nov. 12, 2024: Clinical Practice Update

Learning Objectives:

1. Review the existing policies and regulations pertinent to addiction care and research.
2. Discuss current trends in stimulant use, and related harms, and treatment for stimulant use disorder.
3. Examine effective screening techniques, treatment options, and patient discussions regarding alcohol use and alcohol use disorder.
4. Review cannabis use-related regulations, cannabis as treatment for medical and physical health issues, and how to support patients who are authorized to use medical cannabis.

Day 1: Research Day (Monday, Nov. 11, 2024)

• 7:30-8 a.m. | Registration, networking, coffee, light refreshments
• 8-8:15 a.m. | Welcome and Event Logistics
  Sue Grigson, PhD
• 8:15-8:30 a.m. | Welcome from the College of Medicine Dean
  Karen Kim, MD
  Dean, Penn State College of Medicine
• 8:30-10 a.m. | Session 1: Neuroscience of Addiction
  Moderated by Yuval Silberman, PhD
  • Meg Fox, PhD: Fentanyl causes molecular and functional adaptations to ventral tegmental area neurons depending on downstream projection target
  • Patrick Randall, MD: Deciphering neuroimmune interactions in substance use: Alcohol and nicotine
  • Quinn Wade, PhD: Neuronal adaptations in the anterior cingulate cortex and their association with symptoms of opioid use disorder
  • Sunderland Baker: White matter connectivity differences in early-stage alcohol use disorder: Diffusion tensor and neurite orientation dispersion and density measures of microstructural integrity.

  Substance use disorders are difficult to treat, can lead to significant decreases in critical health outcomes for patients, and can negatively impact clinical management of other diseases. This session will focus on new research on mechanisms related to development of, and risk for, substance use disorder from the neurobiological perspective. The information gained from this session will assist physicians in carrying out their professional responsibilities more effectively and efficiently and increase knowledge of issues related to substance use disorder for patients and other stakeholders, resulting in improved clinical care and patient outcomes.

• 10 -10:15 a.m. | Break
• 10:15-11:45 a.m. | Session 2: Risk for Addiction Development and Relapse
  Moderated by Sue Grigson, PhD
  • Rhea Sullivan, BS: Salivary Micrornas in Infants with Prenatal Opioid Exposure Predict Need for Pharmacotherapy, Required Morphine Treatment Dose, and Presence of Later Neurodevelopmental Delays
  • Tammy Corr, DO: Longitudinal Academic Performance of Children with a History of Neonatal Abstinence Syndrome
  • Tom Gould, PhD: Long-Term Biological and Behavioral Effects of Adolescent Nicotine Exposure
  • Laurel Seemiller, PhD: Adolescent Alcohol Exposure Disrupts Adult Prelimbic Somatostatin Signaling and Behavior in a Sex-Specific Manner in Mice
  • Stephen Sandelich, MD: Perceptions and Attitudes of Adolescents and Caregivers Toward Substance use Screening in the Pediatric Emergency Department
  • Braden Linn, PhD: Changes and more changes: Affect and craving in recovery from alcohol use disorder
  • Carly Brogan: Identifying Risks of Stimulant Use Disorder among Adults on Stimulant Therapy

  While most will have some exposure to addictive substances in their lifetime, only a subset of the population (about 15 – 20%) will develop a substance use disorder. These numbers are largely parallel across the animal and the human data. Thus, here we will learn about factors that increase the likelihood of developing a substance use disorder, and those that are protective. Additionally, like the development of a substance use disorder, only a subset of individuals meets and maintains their recovery goals. Here, we will explore factors that contribute to recurrence of use, the related underlying neural substrates, and possible interventions. By the end of the session, attendees will have a better understanding of substance use disorder/addiction and factors that contribute to its development or maintenance in vulnerable individuals.

• 11:45-12:30 p.m. | Lunch
• 12:30-1:30 p.m. | Virtually presented Keynote: Closing the treatment gap in Alcohol Use Disorder: Challenges and opportunities
  George Koob, PhD

  Objectives

  • Outline the extent of the pathophysiology associated with alcohol misuse and alcohol use disorder
  • Explain the challenges in addressing alcohol misuse and closing the treatment gap
  • Discuss the resources available from the National Institute on Alcohol Abuse and Alcoholism with particular emphasis on the Health Care Professional’s Core Resource on alcohol
• 1:30-1:45 p.m. | Break
• 1:45-3:15 p.m. | Session 3: Novel Drugs and Treatment of Substance Use Disorders
  Moderated by Andrea Hobkirk, PhD
  Introductions: Wesley M. Raup-Konsavage, PhD
  • Jessica Yingst, DrPH: Nicotine Delivery Profiles of New Nicotine Products
  • Sarah Kawasaki, MD: Treatment Retention Trends in Outpatient MOUD Therapy in an RCT using reSET-OTM: A Mobile-App Intervention Providing Cognitive Behavioral Therapy for Opioid Use Disorder Patients
  • Sara Mills-Huffnagle, MS: Acute Minocycline Treatment Attenuates Physical Withdrawal Symptoms but does not Impact Later Cognitive Development in Rat Model of Neonatal Opioid Withdrawal Syndrome (NOWS)
  • Charles Zawatsky: Unregulated Designer Drug Markets Following the 2018 Farm Bill
  • Nathan Morris, MS: Intracranial Cannabigerol Infusion Reduces Neuropathy

  Over the past decade, the United States saw drastic shifts in the regulatory and therapeutic landscape for drugs like cannabis, tobacco, psychedelics, and other psychoactive substances. In response, new drug formulations, modes of administration, and novel therapeutics emerged in the commercial market and healthcare industry. Researchers are working to test the health effects, safety, benefits, and harms of these new drugs in efforts to inform and protect public health. This session on novel drugs and treatments will discuss emerging drugs and novel drug formulations for cannabis, nicotine, and other substances. Key topics will include pharmacokinetics, acute and long-term health effects, and potential therapeutic properties. The speakers will review the latest empirical findings and discuss societal impacts, ethical challenges, and regulatory obstacles for these emerging drugs.  By the end of the session, attendees will have a better understanding of the evolving landscape of drug therapeutics and the future directions of research.

• 3:15-3:30 p.m. | Closing Remarks
  Sue Grigson, PhD
  Erika Saunders, MD
• 3:30-5:30 p.m. | Poster Session and Reception

Day 2: Clinical Day (Tuesday, Nov. 12, 2024)

• 7:30-8 a.m. | Registration, networking coffee, light refreshments
• 8-8:10 a.m. | Welcome and Event Logistics
  Aleksandra Zgierska, MD, PhD
• 8:10-8:30 a.m. | Welcome from the College of Medicine Vice Dean for Research and Graduate Studies
  Leslie Parent, MD
• 8:30-10 a.m. | Session 1: Stimulants Use: Clinical Practice and Research Updates
  James Latronica, DO
  Sarah Kawasaki, MDAs the opioid overdose/poisoning crisis rolls on largely unabated, we have seen shifts in both the drug supply, types of substances, and usage patterns. A rapid increase in stimulant use—especially methamphetamine—and associated morbidity/mortality are poised to potentially become a new but different type of epidemic, one that needs strategies that likely differ from those we employ in service of preventing and treating opioid-related harms. This session will focus on the recent patterns of stimulant use, as well as emerging treatments for stimulant use disorder (StUD). It will also discuss the public health antecedents to and consequences of stimulant use, including stimulant poisoning, and StUD, and how diagnoses for which prescription stimulants may be employed may factor into this paradigm.
• 10 -10:30 a.m. | Break and Visit Posters
• 10:30-noon | Session 2: Alcohol Use: Clinical Practice and Research Updates
  Brad Linn, PhD, MSW, MCMP
  Darius Rastegar, MDAlcohol use disorder, a chronic, relapsing condition, is challenging to treat and contributes to significant morbidity and early mortality. In addition, heavy drinking and binge drinking pose a public health burden in a variety of sociodemographic groups. This session will focus on evidence-based recommended approaches to the treatment of alcohol use disorder across the spectrum of severity, including screening and brief intervention (SBI), management of withdrawal, pharmacotherapies and behavioral care, including an overview of motivational interviewing and relapse prevention strategies. The information gained from this session will assist clinicians in applying evidence-based treatment and to most effectively help their patients.
• Noon-1 p.m. | Lunch
• 1-2 p.m. | Non-CMEKeynoteMoving toward Personalized, Continuing Addiction Treatment: Lessons from Chronic Illness Management

  A Thomas McLellan, PhD

  Over the past 25 years there has been increasing acceptance that most serious addictions are best considered and treated as chronic illnesses.  Concurrently, within chronic care medicine, there has been broad acceptance that personalized, research-proven treatments lead to better engagement, adherence, retention and outcomes.   However, with few exceptions, most contemporary addiction treatments continue to be delivered in acute care-oriented programs, where all patients receive very similar care; and where few research-supported components of care are offered.

  The presentation will review essential elements of research-supported, personalized, chronic illness care drawing contrasts with contemporary addiction treatments.  Specific elements to be covered include: promoting early identification and engagement; offering a full continuum of care; offering a choices of medications and behavioral therapies, using performance monitoring to tailor care;  offering coordinated care for physical and mental illnesses; and providing supportive assistance for patients as they transition the care continuum.

  For each of these core elements, the presentation will discuss conceptual, clinical and policy barriers that have blocked adoption of personalized chronic care in addiction treatment; and offer practical policy and financing changes to remove those barriers and improve addiction care.

• 2-2:30 p.m. | Break and Visit Posters
• 2:30-4 p.m. | Session 3: Cannabis Use: Clinical Practice and Research Updates
  Gretchen Maurer, DOSince the enactment of the Controlled Substance Act of 1970, cannabis (marijuana) has been listed as a Schedule I substance, which indicates no accepted medical value and high misuse potential. With expansion of medical cannabis across the United States and federal plans to reschedule cannabis to Schedule III, clinicians and patients pose questions on the possible benefits versus harms of medical cannabis. This session will describe current regulatory climate and research evidence on cannabis’ efficacy as a therapeutic option for medical and mental health conditions, present patient perspectives on this issue, and address the approach to the monitoring and management of patients who are authorized to use medical cannabis, along with the description of a process required for clinicians to become “authorized prescribers.”
• 4-4:15  p.m. | Closing remarksAleksandra Zgierska, MD, PhD
  Sarah Kawasaki, MD

Sue Grigson, PhD
Chair and Professor of Neural and Behavioral Sciences
Interim Chair of Pharmacology
Penn State College of Medicine

Sarah Kawasaki, MD
Director of the Division of Addiction
Pennsylvania Psychiatric Institute
Associate Professor of Psychiatry and Behavioral Health and Medicine
Penn State College of Medicine

Aleksandra Zgierska, MD, PhD
Jeanne L. and Thomas L. Leaman, MD Endowed Professor and Vice Chair for Research
Department of Family and Community Medicine
Penn State College of Medicine

George Koob, PhD

George F. Koob, is Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA). He is also a Senior Investigator at the Intramural Research Program of the National Institute on Drug Abuse where he directs the Neurobiology of Addiction Laboratory in the Integrative Neurosciences Research Branch.

As an authority on alcohol use disorder, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. He has published over 800 peer reviewed papers, mentored 13 Ph. D students, 85 post-doctoral fellows, 11 K99’s and authored several books including the “Neurobiology of Addiction”. He received his Ph.D. in Behavioral Physiology from Johns Hopkins University in 1972. He did post-doctoral studies at Walter Reed Army Institute of Research and the University of Cambridge (England). He subsequently held positions at The Salk Institute and the Scripps Research Institute. Dr. Koob is the recipient of many honors, including membership in the National Academy of Medicine (USA) and award of the Legion of Honor (France)

A. Tom McLellan, PhD

Emeritus Professor in Psychiatry
Perelman School of Medicine
University of Pennsylvania

A. Thomas McLellan has been a career addiction researcher for 50 years at the Treatment Research Institute (which he founded in 1992) and at the University of Pennsylvania, Perelman School of Medicine in the Department of Psychiatry.

In his career Tom published over 650 research articles and successfully completed over 150 NIH research grants.   He received Lifetime Achievement Awards from the American, Greek, Swedish, Italian, Egyptian and British Societies of Addiction Medicine – and jointly from the US National Institutes on Drug Abuse (NIDA) and on Alcohol Abuse and Alcoholism (NIAAA).

From 2009-2011 Dr. McLellan was Deputy Director of the White House Office of National Drug Control Policy, where he authored President Obama’s National Drug Control Strategy.  In 2016 Tom was Senior Editor on the US Surgeon General’s report Facing Addiction.  Currently, Dr. McLellan is semi-retired in Sarasota Florida but continues to consult and serve on the Boards of Shatterproof, Affect Therapeutics and Recover Together.

Dr. McLellan holds a B.A. from Colgate University and a Ph.D. from Bryn Mawr College.  He received postgraduate training in psychology at Oxford University in England.

James Latronica, DO
Assistant Professor of Psychiatry and Family Medicine
University of Pittsburgh

Darius Rastegar, MD
Associate Professor of Medicine
Medical Director, Addiction Medicine Unit
Johns Hopkins Bayview Medical Center

Sue Grigson, PhD
Chair and Professor of Neural and Behavioral Sciences
Interim Chair of Pharmacology
Penn State College of Medicine

Aleksandra Zgierska, MD, PhD
Jeanne L. and Thomas L. Leaman, MD Endowed Professor and Vice Chair for Research
Department of Family and Community Medicine
Penn State College of Medicine

Yuval Silberman, PhD
Associate Professor of Neural and Behavioral Sciences
Penn State College of Medicine

Andrea Hobkirk, PhD
Assistant Professor of Psychiatry and Behavioral Health
Penn State College of Medicine

Erika Saunders, MD
Chair of Psychiatry and Behavioral Health
Gerald B. Shively and Robert Y. Tan Professor in Biological Psychiatry
Penn State College of Medicine

Brad Lin, PhD, MSW, MCMP
Assistant Professor of Family and Community Medicine
Penn State College of Medicine

Gretchen Maurer, DO
Assistant Professor of Family and Community Medicine
Penn State College of Medicine

Sarah Kawasaki, MD
Director of the Division of Addiction
Pennsylvania Psychiatric Institute
Associate Professor of Psychiatry and Behavioral Health and Medicine
Penn State College of Medicine

AMA

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Penn State College of Medicine designates this live activity for a maximum of 10 AMA PRA Category 1 Credit(s) 5.5 on Nov. 11 and 4.5 on Nov. 12. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses Using AMA Credit

Nurses will receive a certificate from Penn State College of Medicine verifying their participation in up to 10 hours of approved continuing medical education. Continuing education activities which are approved by accredited institutions of higher education and that are relevant to patient care or professional nursing meet the requirements of mandatory continuing education for registered nurses in Pennsylvania, as required by the Pennsylvania State Board of Nursing. The Board of Nursing recommends that nurses retain their certificates for a period of at least five years. Additional information is available through the State Board of Nursing.

APA

Penn State College of Medicine, Department of Psychiatry, is approved by the American Psychological Association to sponsor continuing education for psychologists. Penn State College of Medicine, Department of Psychiatry, maintains responsibility for this program and its content. Full attendance at the sessions and evaluation of each individual session attended is required to receive CE credit for psychologists. Partial credit will not be awarded. Late arrivals or early departures will preclude awarding of CE credits.

There is no fee, but registration is required.

In-person registration closes Nov. 1.

Virtual registration is open through the event.

Accommodations are the responsibility of the program participant.

Days Inn by Wyndham Hershey

350 W. Chocolate Ave, Hershey, PA.
717-534-2162
Discount available through 11/7/2024:  $70 plus tax per night for November 10, 11 and 12
Code: Penn State Addiction Conference
Days Inn by Wyndham Hershey – Guest Reservations

Hilton Garden Inn Hershey

550 East Main Street, Hummelstown, PA 17036
717-566-9292
Corporate Rate available at $169 plus tax per night
When making reservation, let the hotel know guest is with Penn State College of Medicine.
Hilton Garden Inn Hershey – Guest Reservations

A completed evaluation is required in order to receive a certificate for attending this activity. Please complete and submit the evaluation within the specified time frame.

The University reserves the right to cancel or postpone any course or activity because of insufficient enrollment or other unforeseen circumstances. If a program is canceled or postponed, the University will refund any program registration fees paid but cannot be held responsible for any related costs, charges or expenses, including cancellation/change charges assessed by airlines or travel agencies.

Program registrants who are experiencing illness or have been exposed to anyone who is ill should contact the Continuing Education office before attending any in-person activities.

Content and speakers for all programs are subject to change. Registrants will be notified of any significant updates.

On-campus educational activities provided by Penn State College of Medicine Continuing Education are required to follow healthcare facility guidelines. Off-campus events provided by Penn State College of Medicine Continuing Education follow the COVID-19 requirements of that venue. We ask that all participants respect that some attendees may still choose to wear masks for activities. Check the venue website for the latest requirements and recommendations. Please do not attend this activity if you have symptoms or have been exposed to someone with COVID-19. By attending the activity, you attest that you do not have any symptoms suggestive of COVID-19, which may include fever, cough, shortness of breath, sore throat, loss of taste, loss of smell or any other sign of illness.

Penn State encourages people with disabilities to participate in its programs and activities. Participants who anticipate needing any type of special accommodation or who have questions about the physical access provided should contact the Continuing Education office at least one week in advance of participation or visit.

It is Penn State policy to ensure balance, independence, objectivity and scientific rigor in all educational activities. Penn State has a process in place to mitigate any relevant financial relationships with commercial companies disclosed by faculty, course directors and planning committee members. Complete disclosure information will be provided to participants at the beginning of the activity.

This publication is available in alternative media on request. The Pennsylvania State University is committed to the policy that all persons shall have equal access to programs, facilities, admission and employment without regard to personal characteristics not related to ability, performance or qualifications as determined by University policy or by state or federal authorities. It is the policy of the University to maintain an academic and work environment free of discrimination, including harassment. The Pennsylvania State University prohibits discrimination and harassment against any person because of age, ancestry, color, disability or handicap, genetic information, national origin, race, religious creed, sex, sexual orientation, gender identity or veteran status and retaliation due to the reporting of discrimination or harassment. Discrimination, harassment or retaliation against faculty, staff or students will not be tolerated at The Pennsylvania State University. Direct all inquiries regarding the Nondiscrimination Policy to the Affirmative Action Director, The Pennsylvania State University, 328 Boucke Building, University Park, PA 16802-5901; 814-863-0471 (TTY). US M.Ed. J7043